MACROLIDE TOTAL SYNTHESIS

大环内酯全合成

基本信息

  • 批准号:
    3283922
  • 负责人:
  • 金额:
    $ 22.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1985
  • 资助国家:
    美国
  • 起止时间:
    1985-09-01 至 1991-08-31
  • 项目状态:
    已结题

项目摘要

The overall objective of this research program is the development of efficient synthetic procedures for construction of structurally complex macrolide natural products. The specific targets include latrunculin A, acutiphycin, 20,21-didehydroacutiphycin, aplysiatoxin, debromoaplysiatoxin and oscillatoxin A. The latrunculins (A and B) represent a new class of highly potent macrolides that specifically bind to cytoskeletal proteins and thereby disrupt microfilament organization in cultured cells without effecting the microtubular system. The mode of action, while still unknown, most closely resembles the activity displayed by the cytochalasins, the only other class of drugs known to bind to actin filaments and to specifically disrupt the mocrofilamentous structures. The latrunculins, however are 10 to 100 times more active than the cytochalasins. Acutiphycin and 20,21-didehydroacutiphycin are macrolides, isolated from the lipophilic extract of the freshwater algae, Oscillatoria acutissima.3 They display cytotoxicity against KB and NIH/3T3 cells as well as significant antineoplastic activity in vivo against murine Lewis lung carcinoma.3 Aplysiatoxin, debromoaplysiatoxin, and oscillatoxin A, also isolated from algae, are potent tumor promoters possessing complex macrolide structures. Each of the above macrolides represents an extremely important target from the point of view of synthetic chemistry and biological potency (i.e., antitumor or tumor promoter activity). In addition to the above quite specific synthetic targets, a more general underlying and long range aim of this research program is the development of a better understanding of the molecular architecture responsible for the biological properties of these and related macrolides. Thus, as we develop our method of procedure for each of the above targets, we will also introduce various model systems which will be amenable to construction and subsequent screening, such that in the end we will be able to dissect out the critical structural feature of features responsible for the observed biological activities. Once such features are identified, the design of new and possible more effective agents should be feasible.
本研究计划的总体目标是发展

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amos B Smith其他文献

Editorial: The First Three Years.
社论:前三年。
  • DOI:
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Amos B Smith
  • 通讯作者:
    Amos B Smith

Amos B Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amos B Smith', 18)}}的其他基金

Dictyostatin and related prodrugs as candidates for tauopathy treatment
Dictyostatin 和相关前药作为 tau 蛋白病治疗的候选药物
  • 批准号:
    8821175
  • 财政年份:
    2014
  • 资助金额:
    $ 22.28万
  • 项目类别:
Synthesis of Bioactive Natural Products
生物活性天然产物的合成
  • 批准号:
    8008963
  • 财政年份:
    2010
  • 资助金额:
    $ 22.28万
  • 项目类别:
Alzhelmer's Disease Drug Development Program
阿尔茨海默病药物开发计划
  • 批准号:
    7676129
  • 财政年份:
    2008
  • 资助金额:
    $ 22.28万
  • 项目类别:
Alzhelmer's Disease Drug Development Program
阿尔茨海默病药物开发计划
  • 批准号:
    7525036
  • 财政年份:
    2008
  • 资助金额:
    $ 22.28万
  • 项目类别:
Alzhelmer's Disease Drug Development Program
阿尔茨海默病药物开发计划
  • 批准号:
    8118501
  • 财政年份:
    2008
  • 资助金额:
    $ 22.28万
  • 项目类别:
Alzhelmer's Disease Drug Development Program
阿尔茨海默病药物开发计划
  • 批准号:
    7882501
  • 财政年份:
    2008
  • 资助金额:
    $ 22.28万
  • 项目类别:
Alzhelmer's Disease Drug Development Program
阿尔茨海默病药物开发计划
  • 批准号:
    8287605
  • 财政年份:
    2008
  • 资助金额:
    $ 22.28万
  • 项目类别:
Pilot-Scale Libraries for High-throughput Screening
用于高通量筛选的中试规模文库
  • 批准号:
    7291136
  • 财政年份:
    2007
  • 资助金额:
    $ 22.28万
  • 项目类别:
Pilot-Scale Libraries for High-throughput Screening
用于高通量筛选的中试规模文库
  • 批准号:
    7684229
  • 财政年份:
    2007
  • 资助金额:
    $ 22.28万
  • 项目类别:
2D IR OF UNUSUAL ISOTOPOMERS AND FOLDING
异常同位素异构体和折叠的二维红外图
  • 批准号:
    7598434
  • 财政年份:
    2007
  • 资助金额:
    $ 22.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了